Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis

Liu,Ya-Fei; Dong,Hui; Tu,Sheng-Hao; Zheng,Cui-Hong; Liu,Pei-Lin; Hu,Yong-Hong

doi:10.3892/etm.2014.1974

Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis

Authors:
- Ya-Fei Liu
- Hui Dong
- Sheng-Hao Tu
- Cui-Hong Zheng
- Pei-Lin Liu
- Yong-Hong Hu
View Affiliations

Affiliations: Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: September 17, 2014 https://doi.org/10.3892/etm.2014.1974
Pages: 1585-1592

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Etanercept (ETN) has been widely applied in the treatment of ankylosing spondylitis (AS). As the use of ETN has increased, associated adverse effects have been reported frequently. Previous meta‑analyses have focused on comparing the differences in clinical outcomes between ETN and placebo (PBO). The present meta‑analysis evaluated randomised controlled trials (RCTs) to compare the effects of ETN and a PBO or sulfasalazine (SSZ) in patients with AS. The study population characteristics and the main results, including the Assessment in AS 20% response (ASAS 20), the Bath AS Disease Activity Index (BASDAI) and the Bath AS Functional Index (BASFI), were extracted. The pooled odds ratios (ORs) or weighted mean differences (MDs) were calculated using a fixed or random effects model. Fifteen randomised controlled trials (RCTs) involving 2,194 subjects were included. Compared with a PBO, ETN significantly improved the ASAS 20 [P<0.00001; OR, 8.25; 95% confidence interval (CI), 5.92‑11.50], BASDAI (P<0.00001; MD, -18.81; 95% CI, -24.47 to -13.15) and BASFI (P<0.00001; standard MD, -0.68; 95% CI, -0.85 to -0.50). In comparison with SSZ, ETN significantly decreased the BASDAI (P<0.00001; MD, -2.40; 95% CI, -2.89 to -1.90) and C-reactive protein (CRP) levels (P<0.0001; MD, -8.01; 95% CI, -11.73 to -4.29). The most common adverse effect of ETN was an injection site reaction. This meta‑analysis shows that ETN monotherapy is effective in improving physical function and reducing disease activity in patients with AS. Compared with SSZ, ETN markedly decreased the BASDAI and CRP levels. However, the efficacy of ETN in treating AS requires further evaluation by more RCTs in a larger population of patients prior to recommending ETN as a substitute for synthetic disease‑modifying antirheumatic drug (DMARD) monotherapy, or combinations of synthetic DMARDs.

View Figures

View References

1	Braun J and Sieper J: Ankylosing spondylitis. Lancet. 369:1379–1390. 2007. View Article : Google Scholar
2	Feldtkeller E, Khan M, van der Heijde D, et al: Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 23:61–66. 2003.PubMed/NCBI
3	Sieper J and Braun J: Anti-TNF agents for the treatment of spondyloarthropathies. Expert Opin Emerg Drugs. 7:235–246. 2002. View Article : Google Scholar : PubMed/NCBI
4	Gratacos J, Collado A, Filella X, et al: Serum cytokines (IL-6, TNF-α, IL-1β and IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Rheumatology. 33:927–931. 1994.
5	Braun J, Bollow M, Neure L, et al: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 38:499–505. 1995. View Article : Google Scholar : PubMed/NCBI
6	Culy CR and Keating GM: Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs. 62:2493–2537. 2002.PubMed/NCBI
7	Mease PJ, Goffe BS, Metz J, et al: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 356:385–390. 2000. View Article : Google Scholar : PubMed/NCBI
8	Lovell DJ, Giannini EH, Reiff A, et al: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 342:763–769. 2000. View Article : Google Scholar : PubMed/NCBI
9	Braun J, Van den Berg R, Baraliakos X, et al: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 70:896–904. 2011. View Article : Google Scholar : PubMed/NCBI
10	Chen J and Liu C: Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. 18:CD0048002005.
11	Ferraz MB, Tugwell P, Goldsmith CH, et al: Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol. 17:1482–1486. 1990.PubMed/NCBI
12	Li SH, Ma B, Tan JY, et al: Efficacy and safety of etanercept for patients with ankylosing spondylitis: a systematic review. Chinese Journal of Evidence-Based Medicine. 9:423–429. 2009.(In Chinese).
13	Moher D, Liberati A, Tetzlaff J and Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 151:264–269. 2009. View Article : Google Scholar
14	van der Linden S, Valkenburg HA and Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 27:361–368. 1984.
15	Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar
16	Anderson JJ, Baron G, van der Heijde D, et al: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 44:1876–1886. 2001. View Article : Google Scholar : PubMed/NCBI
17	Garrett S, Jenkinson T, Kennedy LG, et al: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 21:2286–2291. 1994.PubMed/NCBI
18	Calin A, Garrett S, Whitelock H, et al: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 21:2281–2285. 1994.PubMed/NCBI
19	Dougados M, Braun J, Szanto S, et al: Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis. 70:799–804. 2011. View Article : Google Scholar
20	Lin Q, Lin Z, Gu J, et al: Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment. Rheumatol Int. 30:317–323. 2010. View Article : Google Scholar : PubMed/NCBI
21	Gorman JD, Sack KE and Davis JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med. 346:1349–1356. 2002.
22	Davis JC Jr, Van Der Heijde D, Braun J, et al; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48:3230–3236. 2003. View Article : Google Scholar
23	Braun J, van der Horst-Bruinsma IE, Huang F, et al: Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial. Arthritis Rheum. 63:1543–1551. 2011. View Article : Google Scholar : PubMed/NCBI
24	Calin A, Dijkmans BAC, Emery P, et al: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 63:1594–1600. 2004. View Article : Google Scholar : PubMed/NCBI
25	van der Heijde D, Da Silva JC, Dougados M, et al; Etanercept Study 314 Investigators. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 65:1572–1577. 2006.PubMed/NCBI
26	Brandt J, Khariouzov A, Listing J, et al: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 48:1667–1675. 2003. View Article : Google Scholar : PubMed/NCBI
27	Huang F, Zhang J, Zheng Y, et al: A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept in the treatment of Chinese patients with active ankylosing spondylitis. Zhonghua Nei Ke Za Zhi. 50:1043–1047. 2011.(In Chinese).
28	Huang F, Zhang J, Huang JL, et al: A multicenter, double-blind, placebo-controlled, randomized clinical study of etanercept in the treatment of ankylosing spondylitis. Zhonghua Nei Ke Za Zhi. 49:741–745. 2010.(In Chinese).
29	Deng XH, Hang F, Zhang YM, et al: Treatment of ankylosing spondylitis with recombinant human tumor necrosis factor-Fc fusion protein (etanercept): a multicenter, randomized, double-blind, placebo-controlled trial. Jun Yi Jin Xiu Xue Yuan Xue Bao. 30:21–23. 2009.(In Chinese).
30	Zhang J, Zhang YM, Zhang JL, et al: Efficacy of etanercept in patients with ankylosing spondylitis: A double-blind, randomized, placebo controlled trial. Zhongguo Xin Yao Za Zhi. 18:1846–1849. 2009.(In Chinese).
31	Zhao WM, Chen ZW and Wang MJ: Clinical observation of etanercept in treatment of ankylosing spondylitis. Suzhou Da Xue Xue Bao. 29:518–523. 2009.(In Chinese).
32	Zhao FT, Zhao H and Wang YL: Efficacy of etanercept on ankylosing spondylitis. Shanghai Jiaotong Daxue Xuebao Yixueban. 29:1506–1508. 2009.(In Chinese).
33	Sterne JA, Gavaghan D and Egger M: Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 53:1119–1129. 2000. View Article : Google Scholar : PubMed/NCBI
34	Davis JC Jr: The role of etanercept in ankylosing spondylitis. Clin Exp Rheumatol. 20(Suppl 28): S111–S115. 2002.PubMed/NCBI
35	Chen MZ, Zhao RGT, Wang HY, et al: Clinical control study of recombinant human tumor necrosis factor-Fc fusion protein and traditional immunity depressant in treatment of ankylosing spondylitis (AS). Xinjiang Yi Ke Da Xue Xue Bao. 33:913–915. 2010.(In Chinese).
36	Machado MA, Barbosa MM, Almeida AM, et al: Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int. 33:2199–2213. 2013. View Article : Google Scholar : PubMed/NCBI
37	Li ZH, Zhang Y, Wang J and Shi ZJ: Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol. 23:497–506. 2013. View Article : Google Scholar : PubMed/NCBI